coIMMUNE welcomes Mike Fekete and Greg Tibbitts to its Board of Directors

– USA, NC –  CoImmune, Inc., a clinical-stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies, today announced the appointments of Michael Fekete and Greg Tibbitts, to its board of directors, bringing a wealth of financial, capital markets, and strategic expertise, and prior board level experience.…